All In Biotech

NDA 216117 · Osmotica Pharm US

Relexxii

Methylphenidate Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jun 23, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

456

101 Phase 3, 37 recruiting

FAERS reports

6,997

4,351 serious, 442 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION RELEXXII has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including RELEXXII, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing RELEXXII, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout RELEXXII treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ) and Drug Abuse and Dependence ( 9.2 )] . WARNING: ABUSE, MISUSE, AND...

What it is approved for

From the label in effect Sep 26, 2025.

RELEXXII is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and pediatric patients 6 years of age and older [ see Clinical Studies ( 14 )] . Limitations of Use The use of RELEXXII is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 )] . RELEXXII ® is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and pediatric patients 6 years of age and older ( 1 ). Limitations of Use The use of RELEXXII is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.7 , 8.4 ).

Mechanism: Methylphenidate HCl is a CNS stimulant. The mode of therapeutic action in ADHD is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 23, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
7 products under this application
  • RELEXXII · METHYLPHENIDATE HYDROCHLORIDE 72MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE TBD
  • RELEXXII · METHYLPHENIDATE HYDROCHLORIDE 54MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE TBD
  • RELEXXII · METHYLPHENIDATE HYDROCHLORIDE 36MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE TBD
  • RELEXXII · METHYLPHENIDATE HYDROCHLORIDE 18MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE TBD
  • RELEXXII · METHYLPHENIDATE HYDROCHLORIDE 63MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE TBD
  • RELEXXII · METHYLPHENIDATE HYDROCHLORIDE 45MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE TBD
  • RELEXXII · METHYLPHENIDATE HYDROCHLORIDE 27MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE TBD

Clinical trials

Interventional ClinicalTrials.gov studies with "Methylphenidate" as an intervention, any sponsor and status, largest first.

All 456 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,049
  • headache399
  • fatigue357
  • anxiety352
  • off label use340
  • nausea333
  • toxicity to various agents333
  • product substitution issue290
  • drug abuse285
  • somnolence271
  • insomnia265
  • disturbance in attention240

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20051
20061
20073
20088
200918
201014
201118
201269
2013117
2014121
2015440
2016343
2017495
2018576
2019459
2020352
2021411
2022611
2023790
2024744
2025728
2026676

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 16, 2026

    Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10).

  • Current · updated Nov 16, 2026

    Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10). Discontinuation of the manufacture of the drug

  • Current · updated Nov 16, 2026

    Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30).

  • Current · updated Nov 16, 2026

    Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10). Discontinuation of the manufacture of the drug

  • Current · updated Nov 16, 2026

    Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30).

  • Current · updated Nov 16, 2026

    Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30). Demand increase for the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Relexxii (Methylphenidate HCl)

2024 spending

$39K

Beneficiaries

26

77 claims

Per beneficiary

$1,503

$15.64 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$39,088

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,058 on PubMed

Sponsor: Osmotica Pharm US

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.